Aromatase and the breast: Regulation and clinical aspects

Maturitas

Volumn 54, Issue 4, 2006, Pages 335-341

  Miller, W R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Aromatase; Breast cancer; Oestrogen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CYCLIC AMP; EXEMESTANE; FORMESTANE; JANUS KINASE; LETROZOLE; STAT PROTEIN;

ADIPOSE TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER SIZE; DRUG COMPETITION; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; ESTROGEN ACTIVITY; ESTROGEN BLOOD LEVEL; ESTROGEN SYNTHESIS; EXON; FIBROBLAST CULTURE; HUMAN; IC 50; POSTMENOPAUSE; PROMOTER REGION;

AROMATASE; AROMATASE INHIBITORS; BREAST; BREAST NEOPLASMS; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; ESTROGENS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS;

EID: 33745713939     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.04.020     Document Type: Article

References (70)

1. Miller W.R. Estrogen and breast cancer (1996), RG Landes & Co.
2. Judd H.L., Judd G.E., Lucas W.E., and Yen S.S. Endocrine function of the postmenopausal ovary: concentration of androgen and estrogens in ovarian and peripheral vein blood. J Clin Endocrinol Metab 39 (1974) 1020-1024
3. Baird D.T., Uno A., and Melby J.C. Adrenal secretion of androgens and estrogens. J Endocrinol 45 (1969) 135-136
4. Perel E., and Killinger D.W. The interconversion and aromitization of androgens by human adipose tissue. J Steroid Biochem 10 (1979) 623-627
5. Schweikert H.U., Milewich L., and Wilson J.D. Aromatization of androstenedione by cultured human fibroblasts. J Clin Endocrinol Metab 43 (1976) 785-795
6. Larionov A.A., Vasyliev D.A., Mason J.I., et al. Aromatase in skeletal muscle. J Steroid Biochem Mol Biol 84 (2003) 485-492
7. Smuk M., and Schwers J. Aromatization of androstenedione by human adult liver in vitro. J Clin Endocrinol Metab 45 (1977) 1009-1012
8. Vermeulen A. Human mammary cancers as a site of sex steroid metabolism. Cancer Surv 5 (1986) 585-595
9. Miller W.R. Uptake and synthesis of steroid hormones by the breast. Endocr Relat Cancer 4 (1997) 307-311
10. Miller W.R., Mullen P., Sourdaine P., Watson C., Dixon J.M., and Telford J. Regulation of aromatase activity within the breast. J Steroid Biochem 61 (1997) 193-202
11. Bulun S.E., and Simpson E.R. Regulation of aromatase expression in human tissues. Breast Cancer Res Treat 30 (1994) 19-29
12. Reed M.J., Aherne G.W., Ghilchik M.W., Patel S., and Chakraborty J. Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues. Int J Cancer 49 (1991) 562-565
13. James V.H.T., Reed M.J., Adams E.F., et al. Estrogen uptake and metabolism in vivo. In: Beck J.S. (Ed). Estrogen and the human breast vol. 95B (1989), The Royal Society of Edinburgh, Edinburgh 185-193
14. Bezwoda W.R., Mansoor N., and Dansey R. Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. Oncology 44 (1987) 345-349
15. Miller W.R., and O'Neill J.S. The importance of local synthesis of estrogen within the breast. Steroids 50 (1987) 345-349
16. Miller W.R., and Anderson E.C. The biological relevance of aromatase activity in breast tumours. In: Robustelli Della Cuna G., Manni A., and Pannutti F. (Eds). Clinical use of aromatase inhibitors, current data and future perspectives (1995), Edizioni Medico Scientifiche, Pavia 89-93
17. Miller W.R., Anderson T.J., Evans D.B., Krause A., Hampton G., and Dixon J.M. An integrated view of aromatase and its inhibiton. J Steroid Biochem Mol Biol 86 (2003) 413-421
18. Miller W.R. Importance of intratumour aromatase, and its susceptibility to inhibitors. In: Doswett M. (Ed). Aromatase Inhibition - then, now and tomorrow (1994), Partenon Publishing Group, London 43-53
19. 2. Endocr Relat Cancer 6 (1999) 139-147
20. Miller W.R., and Mullen P. Factors influencing aromatase activity in the breast. J Steroid Biochem Mol Biol 44 (1993) 597-604
21. Simpson E.R., and Mendelson C.R. The regulation of oestrogen biosynthesis in human adipose tissue. Proc R Soc Edinb 95B (1989) 153-159
22. Zhao Y., Nichols J.E., Bulun S.E., Mendelson C.R., and Simpson E.R. Aromatase P450 gene expression in human adipose tissue. Role of a Jak/STAT pathway in regulation of the adipose-specific promoter. J Biol Chem 270 (1995) 16449-16457
23. Purohit A., Ghilchik M.W., Duncan L.J., et al. Aromatase activity and interlukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab 80 (1995) 3052-3058
24. Reed M.J., and Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocr Rev 18 (1997) 701-715
25. Macdiarmid F., Wang D., Duncan L.J., Purohit A., Ghilchick M.W., and Reed M.J. Stimulation of aromatase activity in breast fibroblasts by tumour necrosis factor alpha. Mol Cell Endocrinol 106 (1995) 17-21
26. Zhao Y., Nichols J.E., Valdez R., Mendelson C.R., and Simpson E.R. Tumor necrosis factor-alpha stimulates aromatase gene expression in human adipose stromal cells through use of an activating protein-1 binding site upstream of promoter 1.4. Mol Endocrinol 10 (1996) 1350-1357
27. Means G.D., Kilgore M.W., Mahendroo M.S., Mendelson C.R., and Simpson E.R. Tissue-specific promoters regulate aromatase cytochrome P450 gene expression in human ovary and fetal tissues. Mol Endocrinol 5 (1991) 2005-2013
28. Bulun S.E., Zeitoun K., Sasano H., and Simpson E.R. Aromatase in aging women. Semin Reprod Endocrinol 17 (1999) 349-358
29. Harada N., Utsumi T., and Takagi Y. Tissue specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters and switching of tissue specific exons 1 in carcinogenesis. Proc Natl Acad Sci USA 90 (1993) 11312-11316
30. Harada N., and Yamada K. Ontogeny of aromatase messenger-ribonucleic-acid in mouse brain-fluorometrical quantitation by polymerase chain-reaction. Endocrinology 131 (1992) 2306-2312
31. Howie A.F., Morley S.D., Miller W.R., and Mason J.I. Aromatase transcripts in breast cancer. Proceedings of the aromatase and its inhibitors (1998) [abstract 11]
32. Harada N., and Honda S. Molecular analysis of aberrant expression of aromatase in breast cancer. Breast Cancer Res Treat 49 (1998) S15-S21
33. Chen S., Zhou D., Okubo T., Kao Y.C., and Yang C. Breast tumour aromatase: functional role and transcriptional regulation. Endocr Relat Cancer 6 (1999) 149-156
34. Wang J., and Chen S. Identification of a promoter and a silencer and the 3′-end of the first intron of the human aromatase gene. Mol Endocrinol 6 (1992) 1479-1488
35. Zhou D., and Chen S. Characterization of a silencer element in the human aromatase gene. Arch Biochem Biophys 315 (1998) 213-220
36. Jin T., Zhang X., Li H., and Goss P.E. Characterization of a novel silencer element in the human aromatase gene II promoter. Breast Cancer Res Treat 62 (2000) 151-159
37. Yang C., Zhou D.J., and Chen S. Modulation of aromatase expression in the breast tissue by ERR alpha-1 orphan receptor. Cancer Res 58 (1998) 5695-5700
38. Harada N. Aberrant expression of aromatase in breast cancer tissues. J Steroid Biochem Mol Biol 61 (1997) 175-184
39. Agarwal V.R., Bulun S.E., Leitch M., Rohrich R., and Simpson E.R. Use of alternative promoters to express the aromatase cytochrome P450 (CYP19) gene in breast adipose tissue of cancer-free and breast cancer patients. J Clin Endocrinol Metab 81 (1996) 3843-3849
40. Miller W.R., Anderson T.J., and Jack W.J.L. Relationship between tumour aromatase activity, tumour characteristics and response to therapy. J Steroid Biochem Mol Biol 37 (1990) 1055-1059
41. O'Neill J.S., and Miller W.R. Aromatase activity in adipose tissue from women with benign and malignant breast disease. Br J Cancer 56 (1987) 601-604
42. O'Neill J.S., Elton R.A., and Miller W.R. Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. Br Med J 296 (1988) 741-743
43. Abul-Hajj Y.J., Iverson R., and Kiang D.T. Aromatization of androgens by human breast cancer. Steroids 33 (1979) 205-222
44. Miller W.R. Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 16 (1989) 83-93
45. Brodie A.M., Brodie H.J., Romanoff L., Williams J.G., Williams K.I., and Wu J.T. Inhibition of estrogen biosynthsis and regression of mammary tumors by aromatase inhibitors. Adv Exp Med Biol 138 (1981) 179-190
46. Lonning P.E. Pharmacology and clinical experience with exemestane. Expert Opin Invest Drugs 9 (2000) 1897-1905
47. Graham-Lorence S., and Peterson J.A. P450s: structural similarities and functional differences. FASEB J 10 (1996) 206-214
48. Plourde P.V., Dyroff M., and Dukes M. Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 30 (1994) 103-111
49. Iveson T.J., Smith I.E., Ahern J., Smithers D.A., Trunet P.F., and Dowsett M. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 53 (1993) 266-270
50. Miller W.R., and Jackson J. The therapeutic potential of aromatase inhibitors. Expert Opin Invest Drugs 12 (2003) 1-15
51. Bhatnagar A.S., and Miller W.R. Pharmacology of inhibitors of estrogen biosynthesis. In: Oettel M., and Schillinger E. (Eds). Handbook of experimental pharmacology: estrogens and antiestrogens (1999), Springer-Verlag, Berlin 223-230
52. Lonning P.E. Pharmacology of new aromatase inhibitors. Breast 5 (1996) 202-208
53. Geisler J., King N., Anker G., et al. In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 4 (1998) 2089-2093
54. Miller W.R., and Dixon J.M. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 79 (2001) 93-102
55. MacNeill F.A., Jones A.L., Jacobs S., Lonning P.E., Powles T.J., and Dowsett M. The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 66 (1992) 692-697
56. Jones A.L., MacNeill F., Jacobs S., Lonning P.E., Dowsett M., and Powles T.J. The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients. Eur J Cancer 10 (1992) 1712-1716
57. Lonning P.E., Jacobs S., Jones A., Haynes B., Powles T., and Dowsett M. The influence of CGS 16969A on peripheral aromatisation in breast cancer patients. Br J Cancer 63 (1991) 789-793
58. Dowsett M., Jones A., Johnston S.R., Jacobs S., Trunet P., and Smith I.E. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1 (1995) 1511-1515
59. Geisler J., King N., Dowsett M., et al. Influence of anastrozole (Arimidex), a selective non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma estrogen levels in postmenopausal women with breast cancer. Br J Cancer 74 (1996) 1286-1291
60. Thurlimann B., Paridaens R., Serin D., et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimde: a phase II multicentre multi-national trial. Eur J Cancer 33 (1997) 1767-1773
61. Dixon J.M. Neoadjuvant therapy: surgical perspectives. In: Miller W.R., and Ingle J.N. (Eds). Endocrine therapy in breast cancer (2002), Marcel Dekker, New York 197-212
62. Dixon J.M., Love C.D.B., Renshaw L., et al. Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 6 (1999) 227-230
63. Miller W.R., Anderson T.J., Marson L., et al. Histological changes in breast cancers following primary systemic treatment with either letrozole or tamoxifen. Breast 8 (1999) 216
64. Anderson T.J., Dixon J.M., Stuart M., Sahmend T., and Miller W.R. Effect of neoadjuvant treatment with Anastrozole (Arimidex) on pathological markers in tumors in postmenopausal women with large (>3 cm) operable breast cancer. Proc Am Assoc Cancer Res (2000) [abstract 4708]
65. Eiermann W., Paepke S., Appfelstaedt J., and Letrozole Neoadjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole. A randomized double-blind multicenter study. Ann Oncol 12 11 (2001) 1527-1532
66. Mouridsen H., Gershanovich M., Sun Y., et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a Phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19 10 (2001) 2596-2606
67. ®) compared to tamoxifen as first-line hormonal therapy for advanced breast cancer. Breast Cancer Res Treat 69 (2001) 211
68. The ATAC Trialist's Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 9324 (2002) 2131-2139
69. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after 5 years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
70. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after 2-3 years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092